As the latest American Heart Association (AHA) scientific statement notes, populations are becoming older and heavier -- and high blood pressure (BP) that resists all treatment approaches is thus ...
Yonsei University College of Medicine-led research has shown amiloride is as effective as spironolactone in reducing systolic blood pressure (SBP) over 12 weeks in patients with resistant hypertension ...
Presenter/Lead Investigator: Deepak L. Bhatt, MD, MPH, MBA, Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai and Director of Mount Sinai Fuster Heart ...
Primary hyperaldosteronism may account for a sizable share of resistant hypertension, yet experts say most cases still go ...
The novel aldosterone synthase inhibitor baxdrostat has met its primary and secondary endpoints in the BaxHTN trial of patients with uncontrolled or treatment-resistant hypertension, according to ...
Please provide your email address to receive an email when new articles are posted on . Resistant and refractory hypertension represent distinct disease states requiring different treatments. A ...
MADRID -- For uncontrolled or treatment-resistant hypertension, adding the novel aldosterone synthase inhibitor baxdrostat improved blood pressure in the randomized BaxHTN trial. Seated systolic blood ...
As a result, the average age of male patients with resistant hypertension was 61.7 years, which is 8.2 years younger than the average age of 69.9 for female patients. However, the ratio of male ...
Presenter/Lead Investigator: Deepak L. Bhatt, MD, MPH, MBA, Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai and Director of Mount Sinai Fuster Heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results